Adlai Nortye Group Ltd.

What they do

Adlai Nortye is a Cayman Islands holding company that operates through subsidiaries in the United States and mainland China, including Hangzhou Adlai Biopharma Co., Ltd. The company is engaged in research and development of drug candidates for cancer treatment. It has no approved products and generates no product revenue; operations are focused on preclinical studies and clinical trials. The company's ordinary shares trade on the Nasdaq Global Market as American Depositary Shares, each representing three Class A ordinary shares.

Revenue drivers

• No commercial products — The company has no approved drugs and therefore no product sales. It relies on financing activities to fund research and development.
• Collaboration and licensing arrangements — Any revenue would come from potential licensing deals or collaborations, but the filing does not specify any current revenue-generating agreements.
• Government grants — The company may receive grants from government entities, but no specific amounts or agreements are disclosed in the filing excerpts.

Recent performance

The filing excerpts do not include financial results for the fiscal year ended December 31, 2025. The company reported 120,000,803 ordinary shares outstanding as of that date, consisting of 103,010,803 Class A and 16,990,000 Class B shares. No revenue, net income, or cash position figures are provided in the available text. As a clinical-stage company, it likely incurred operating expenses without product revenue, but specific amounts are not available.

Strategy

The company's stated strategy, as indicated in forward-looking statements, includes advancing preclinical studies and clinical trials for its drug candidates. It aims to obtain relevant regulatory approvals and potentially enter into partnerships or collaborations. The filing emphasizes business strategies and plans to achieve them, but specific details are not provided in the excerpts. The company's operations are conducted through subsidiaries in the U.S. and mainland China, suggesting a focus on both markets.

Risks

• Clinical and regulatory risk — The company's drug candidates are in preclinical and clinical stages, and there is no guarantee they will receive regulatory approval or achieve commercial success.
• Funding risk — With no product revenue, the company depends on external financing to fund its operations and may face challenges raising additional capital.
• Foreign private issuer status — As a Cayman Islands company with operations in China, it is subject to regulatory and geopolitical risks associated with foreign operations, including potential changes in U.S.-China relations.
• Early-stage company — The company has a limited operating history and faces significant uncertainties inherent in developing novel biopharmaceutical products.

Outlook

The filing does not provide specific guidance or outlook statements. The company's forward-looking statements focus on the timing and results of preclinical studies and clinical trials, and the potential to obtain regulatory approvals. Management's priorities likely include advancing its pipeline and securing funding, but no concrete details are disclosed in the excerpts.